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Neuroprotective effects of Sonic hedgehog agonist SAG in a
rat model of neonatal stroke
Vien Nguyen 1,2, Manideep Chavali1,2, Amara Larpthaveesarp1, Srikirti Kodali3, Ginez Gonzalez3, Robin J. M. Franklin3,
David H. Rowitch1,2,3,4 and Fernando Gonzalez1
BACKGROUND: Neonatal stroke affects 1 in 2800 live births and is a major cause of neurological injury. The Sonic hedgehog (Shh)
signaling pathway is critical for central nervous system (CNS) development and has neuroprotective and reparative effects in
different CNS injury models. Previous studies have demonstrated beneficial effects of small molecule Shh-Smoothened agonist
(SAG) against neonatal cerebellar injury and it improves Down syndrome-related brain structural deficits in mice. Here we
investigated SAG neuroprotection in rat models of neonatal ischemia–reperfusion (stroke) and adult focal white matter injury.
METHODS: We used transient middle cerebral artery occlusion at P10 and ethidium bromide (EB) injection in adult rats to induce
damage. Following surgery and SAG or vehicle treatment, we analyzed tissue loss, cell proliferation and fate, and behavioral
outcome.
RESULTS: We report that a single dose of SAG administered following neonatal stroke preserved brain volume, reduced gliosis,
enhanced oligodendrocyte progenitor cell (OPC) and EC proliferation, and resulted in long-term cognitive improvement. Single-
dose SAG also promoted proliferation of OPCs following focal demyelination in the adult rat.
CONCLUSIONS: These findings indicate benefit of one-time SAG treatment post insult in reducing brain injury and improving
behavioral outcome after experimental neonatal stroke.
Pediatric Research _#####################_ ; https://doi.org/10.1038/s41390-021-01408-7
IMPACT:
● A one-time dose of small molecule Sonic hedgehog agonist protected against neonatal stroke and improved long-term
behavioral outcomes in a rat model.
● This study extends the use of Sonic hedgehog in treating developing brain injury, previously shown in animal models of Down
syndrome and cerebellar injury.
● Sonic hedgehog agonist is one of the most promising therapies in treating neonatal stroke thanks to its safety profile and low
dosage.
INTRODUCTION
Neonatal stroke (NS) results from large cerebral vessel disease and
is an important cause of morbidity comprising long-term motor
and/or cognitive deficits.1 With an incidence of 1 in 2800 live births,
NS is more common than adult large vessel stroke. Secondary
injury following arterial ischemia and reperfusion can lead to cell
death, oxidative stress, inflammation, and altered cell proliferation
and fate.2 Cerebral white matter is also highly vulnerable to
ischemic injury during the neonatal period, resulting in significant
functional impairment,3 which in part reflects adverse effects on
oligodendrocyte lineage cells. Indeed, oligodendrocyte progenitor
cells (OPCs) continue to undergo significant changes during the
perinatal and postnatal period and are vulnerable to ischemic
injury.4 Currently, we lack neuroprotective therapies for NS.
Sonic hedgehog (Shh) signaling plays a crucial role in early
central nervous system (CNS) development, influencing
oligodendrocyte development.5 Shh is a secreted protein that
functions by inhibiting the transmembrane receptor Patched
and inducing activity of Smoothened, allowing for activation of
downstream pathway targets, including Gli1 and Cyclin D1
(CCD1). The cilium is present on neural stem cells and has
recently been shown to be present in OPCs but absent in
mature oligodendrocytes, corresponding to loss of responsive-
ness to Shh.5 In addition, astroglial-secreted Shh has been
shown to play a role in blood–brain barrier (BBB) maturation
and maintenance, along with post-insult anti-inflammatory
effects.6
SAG is a small molecule agonist of the Smo-Shh pathway. We
have previously demonstrated efficacy of SAG treatment in a
mouse model of neonatal cerebellar injury.7 In addition, SAG
treatment starting at birth has also been found to be beneficial in
a mouse model of Down syndrome.8 However, these models are
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distinct from the forebrain injury commonly seen in human
preterm and full-term neonates.
We have previously described a non-hemorrhagic
ischemia–reperfusion focal stroke model in the P10 immature
rat using transient unilateral middle cerebral artery occlusion
(tMCAO).9 tMCAO mimics large vessel NS and is thus suitable for
testing pathobiology and post-injury treatment strategies. For
instance, we have described alterations in neural precursor cell
fate following tMCAO that affects both the subcortical white
matter and cortical/subcortical gray matter.9 Oligodendrocyte
injury leads to loss of myelin sheaths, which are important for
metabolic support and transmission of action potentials.10
Oligodendrocyte maturation arrest is observed in neonatal white
matter injury.11 Therefore, enhancing and optimizing the endo-
genous oligodendrocyte response could improve long-term
outcomes. To further elucidate oligodendrocyte biology following
demyelinating injuries, we used the adult cerebellar peduncle
focal demyelination model as it has been well characterized.12
There has been a significant focus on developing therapeutic
strategies using biologics to enhance endogenous repair processes
following brain injury. Recent studies have shown preserved
neuronal numbers, angiogenesis, and improved outcomes following
Shh or SAG treatment in adult stroke models.13 Here we investigated
the neuroprotective effects of SAG in two distinct models of focal
brain injury: (1) neonatal unilateral MCA ischemia–reperfusion in the
immature rat, and (2) focal toxin-induced demyelinating cerebellar
peduncle white matter injury in the mature rat. We examined both
short-term histological and long-term behavioral outcomes after
early stroke and SAG-mediated cell-type-specific effects on forebrain
gray and white matter parenchyma.
METHODS
All animal research was approved by the University of California-
San Francisco and University Biomedical Services of the University
of Cambridge Institutional Animal Care and Use Committees and
in compliance with United Kingdom Home Office regulations.
Preparation of SAG and vehicle
Synthesis of SAG was performed as described previously.14 SAG
was dissolved to 5mM in dimethyl sulfoxide (DMSO) and then
further diluted in normal saline to contain 5% DMSO.
In vivo SAG bioactivity
SAG was injected in Gli-Luciferase reporter mice15 at a concentra-
tion of 50mg/kg body weight. Mice were anesthetized with
isoflurane and placed in an in vivo bioluminescent imaging system
(Xenogen) to detect luciferase reaction. SAG bioactivity was
visualized by increase in intensity in transgenic animals.
Transient middle cerebral artery occlusion
Postnatal day 10 (P10) Sprague-Dawley rats underwent focal
ischemia–reperfusion with tMCAO for 3 h or sham surgery, as
previously described.9 The right internal carotid artery (ICA) was
dissected and an arteriotomy was made proximal to the isolated
ICA. A silicone-coated 6–0 nylon filament was inserted 9–10.5mm
to occlude the MCA and secured for the duration of occlusion.
Following induction, rectal temperature was monitored and
maintained at 36–37 °C with a combination of heating blanket
and overhead light until recovery from anesthesia. For reperfusion,
each animal was anesthetized, and suture ties and the occluding
filament were removed. Avitene Microfibrillar Collagen Hemostat
was placed over the arteriotomy and the skin incision was closed.
Sham animals were anesthetized, and the ICA was dissected, after
which the skin incision was closed. Immediately following
reperfusion, animals received a single intraperitoneal (IP) injection
of SAG (50mg/kg) or vehicle. Weight was monitored for 1 week
following tMCAO or sham surgery to ensure adequate weight gain.
Thirty-two animals underwent tMCAO, and 22 animals sham
surgery (54 animals in total). Animals were split into four groups
(Sham+Veh, n= 5; Sham+SAG, n= 5; tMCAO+Veh, n= 8; tMCAO
+SAG, n= 8, Supplementary Fig. S1) for cell fate analysis at 2 weeks
post-surgery and then were injected with bromodeoxyuridine
(BrdU; 25mg/kg twice daily) from age P11 to P15 to label newly
generating cells. For the second cohort of animals, behavioral
analysis was performed at 2 months of age (Sham+Veh, n= 6;
Sham+SAG, n= 6; tMCAO+Veh, n= 8; tMCAO+SAG, n= 8).
Western blot analysis and quantitative reverse transcription-PCR
(qRT-PCR)
Tissue lysates were obtained from ipsilateral and contralateral
cortices of Sham+Veh, Sham+SAG, tMCAO+Veh, and tMCAO
+SAG 24 h post-reperfusion or equivalent (n= 3 per group). For
protein analysis, fresh-frozen tissues were homogenized in RIPA
buffer (Thermo Scientific) containing protease inhibitors (Roche).
Immunoblotting and fluorescent detection were done as pre-
viously described using the Odyssey system (Li-Cor).4 Antibodies
included CCD1 (rabbit polyclonal, Thermo), Iba1 (rabbit polyclonal,
Wako), glial fibrillary acidic protein (GFAP; mouse monoclonal,
Sigma), and β-Actin (mouse ascites, Sigma). For qRT-PCR, RNA was
isolated with Trizol followed by RNeasy (Qiagen) from tissue
lysates and assayed for Gli1 gene expression with SYBR-Green
(Roche) on a LightCycler 480 (Roche).
Histology
Animal brains were harvested at either 2 weeks post-surgery or
following completion of behavioral testing at 2 months, as
previously described.16 The entire brain was sectioned at 50-µm
intervals on a sliding microtome (Thermo), and serial sections were
mounted, dried, and stained with Cresyl Violet or the following
antibodies: BrdU [Rat Mab BU1/75(ICR1), Accurate Chemicals],
Olig2 (Mouse Mab from C.D. Stiles, Harvard), GFAP (Rat Mab 2.2B10,
Thermo), Iba1 (Rabbit Pab, Wako), CC1 (APC, Mouse Mab OP80,
Calbiochem), Nkx2.2 (Mouse Mab 74.5A, Developmental Studies
Hybridoma Bank), Collagen 4A (Col4A; Goat Pab, AB769 Millipore),
Claudin 5 (Mouse Mab, 35-2500 Invitrogen).
Focal demyelination in cerebellar white matter
Young CD rats (10–12 weeks old, Charles River) were used for the
surgical procedures. Ethidium bromide (EB; 0.01%) was injected
into the rat caudal cerebellar peduncle bilaterally to induce
demyelination as previously described.12 Animals in the treatment
group received SAG (50 mg/kg) IP 5 days post injury (dpi) while
control (sham) group received a single injection of saline IP at the
same time point. OPC recruitment, proliferation, and differentia-
tion are key for successful remyelination. To avoid the acute
effects in this model on OPC proliferation and recruitment and
focus on later repair, treatment was administered 5 days following
EB injection as previously published.17,18 Treatment and sham
animals were perfused at 7 or 14 dpi to study histology. Frozen
sections (12 µm) were collected using a cryostat (Bright Instru-
ments). Oligodendrocyte proliferation and maturation were
studied at 7 dpi (Nkx2.2, Sham+Veh, n= 4, Sham+SAG, n= 3;
Nkx2.2/Ki67, Sham+Veh, n= 4, Sham+SAG, n= 3; Olig2/CC1,
Sham+Veh, n= 4, Sham+SAG, n= 4; PLP, Sham+Veh, n= 3,
Sham+SAG, n= 4), while mature oligodendrocytes were studied
at 14 dpi (Olig2/CC1, Sham+Veh, n= 5,Sham+SAG, n= 5; PLP,
Sham+Veh, n= 4, Sham+SAG, n= 3; Supplementary Fig. S1).
In situ hybridization
The expression of proteolipid protein (Plp) mRNA (1:2000) in
demyelinated lesions was examined by in situ hybridization with
digoxigenin-labeled cRNA probes on cryostat sections (12 μm)
using the established protocols.19 ImageJ 1.44 (Wayne Rasband)
was used to determine the number of positive cells within the
lesions on digitized sections.
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Cylinder Rearing (CR) was used to assess the effects of ischemic
injury and SAG treatment on forelimb use as a function of
sensorimotor bias, as previously described.20 Animals were
handled for about 5 min per day for 3 days prior to testing, which
was conducted 7.5 weeks after surgery. Each animal was then
individually placed in a transparent Plexiglass cylinder (20-cm
diameter, 30-cm height) and observed for 3-min trial on 2
consecutive days, with results averaged per animal. Initial forepaw
placement of each weight-bearing contact with the wall was
recorded as right, left, or both forepaws. Results were expressed as
the percentage use of the non-impaired (right) forepaw for braces
relative to the total number of forepaw initiations.
Novel Object Recognition (NOR) was performed to assess
recognition memory at 8 weeks following surgery.21 Habituation
was performed on days 1 and 2, for a 10-min trial each day, in a
40 cm × 40 cm box with 30 cm tall walls in a room lacking
distinctive navigational cues. A 5-min familiarization trial was
performed on day 3, with two identical objects inside the testing
box. Finally, a 3-min testing phase or NOR trial was performed on
day 4, 24 h following the familiarization phase, where one familiar
object was replaced by a new object of the same size. The animal
exploration time of the novel object was recorded: novel object
preference index (%)= novel object exploration time/(NOR time
+ familiar object exploration time) × 100.
Stereological analysis
Unbiased, systematic random sampling was used to quantify both
hemisphere and corpus callosum (CC) volume. A series represent-
ing every 12th section was selected, Cresyl Violet stained, and
analyzed. Sections encompassed the whole brain rostrally from
the genu of the CC through the posterior portion of the
hippocampus to the occipital lobes caudally. All volumetric
quantifications were performed in a blinded manner on a Zeiss
AxioScope Imager Z.2 with a motorized stage, with the
Neurolucida and Stereoinvestigator software (MicroBrightField).
For the regions of interest (ROIs), the ipsilateral (lesioned) and
contralateral (control) hemispheres (×4 magnification) and CC
(×10) were traced. The cross-sectional area of the ROI was
calculated according to the Cavalieri principle, as previously
published.22 Damage secondary to stroke was determined
quantitatively by calculating the percentage of volume of the
ipsilateral vs contralateral hemispheres.
For quantitative analysis of cell types, a systematic random
sampling of every 24th coronal section (3–4 sections per animal)
was single or double immunostained. Sections were imaged using
a Zeiss AxioImager.A2 upright microscope and analyzed using
Stereoinvestigator. On each section, a tile scan of the entire
hemisphere was imaged, the ROI (striatum or CC) was outlined,
and the ×20 field was randomly placed within the ROI for imaging.
Following imaging of the full-thickness z stack (1-µm steps) with
10-µm border zones, the field was moved in an automated fashion
resulting in imaging of approximately 18% of the ROI. Single and
co-labeled cells were quantified using the Optical Fractionator
probe for unbiased cell counting within the software. Cell density
was calculated as average number of cells per ×20 field, cell
percentage was calculated as the total number of co-labeled cells
per single label, and total cell number in the CC was calculated
using Nv × Vref calculation based on density and volume of the
measured CC, respectively.
Statistical analysis
Data are presented as mean ± SEM. Sex was equally distributed
between groups and time points, and no differences were seen
between female and male animals. All analyses were conducted
by investigators blinded to the treatment group. For statistical
analysis, nonparametric methods were used. The one-way analysis
of variance Kruskal–Wallis test was applied for comparisons of
multiple groups followed by the Wilcoxon rank-sum test for
comparison between the two groups. p Values were corrected by
the Bonferroni method to maintain the α value at 0.05. All
statistical analyses were performed using the SAS Enterprise Guide
software (SAS Institute, Cary, NC, U.S.A.).
RESULTS
Single-dose SAG treatment preserves brain volume following
neonatal tMCAO
We determined the optimal concentration of SAG (50 mg/kg) by
dose–response in vivo using Gli-luciferase mice injected at P10
and followed for 120 h (Supplementary Fig. S2), where we saw
elevated luciferase signal for at least 72 h. We tested different
doses in rats (10–100mg/kg body weight, data not shown), and
found that 50 mg/kg resulted in the most potent changes similar
to our results in mice. To determine the efficacy of post-insult one-
time SAG treatment on forebrain injury in the immature brain, we
performed 3-h tMCAO or sham surgery in P10 rat pups that were
then treated with SAG or vehicle at the time of reperfusion
(Fig. 1a). In rats, P10 is considered a rough developmental
equivalent to the full-term human neonate, when NS is most
common. Prior work has shown that the tMCAO model
consistently results in moderate injury involving the ipsilateral
striatum, subcortical white matter, and parieto-temporal cortex.9
Both sham-operated animals that received SAG or vehicle
treatment (Sham+Veh= 0.98 ± 0.03, Sham+SAG= 1.01 ± 0.04;
Fig. 1b, c) showed minimal hemispheric impact. While tMCAO
+Veh animals showed consistent, significant hemispheric volume
loss 2 weeks following tMCAO (tMCAO+Veh= 0.61 ± 0.04; p <
0.001), single-dose SAG treatment at the time of reperfusion
significantly preserved hemispheric brain volume in tMCAO
animals (tMCAO+Veh= 0.61 ± 0.04, tMCAO+SAG= 0.82 ± 0.03;
p < 0.01), including the CC (tMCAO+Veh= 0.565 ± 0.04; tMCAO
+SAG= 0.732 ± 0.05, p < 0.05, Fig. 1d), almost to sham levels. Thus
there is a significant neuroprotective effect of a one-time SAG
treatment following a tMCAO ischemic insult.
SAG treatment activates downstream Shh targets in the ipsilateral
hemisphere and reduces gliosis following neonatal tMCAO
To confirm that SAG administration targets the Shh pathway, we
performed protein/gene expression analysis from brain samples
collected 24 h after reperfusion to determine the expression of
downstream Shh targets CCD1 and Gli1. Both CCD1 (Fig. 2a, b)
and Gli1 (Fig. 2c) showed significantly increased protein (CCD1)
and gene expression (Gli1) levels in the tMCAO+SAG group
(CCD1 Ipsi/Contra expression ratio: tMCAO+Veh= 0.60 ± 0.047,
tMCAO+SAG= 1.5 ± 0.26, p < 0.05; Gli1 Ipsi/Contra expression
ratio: tMCAO+Veh= 0.24 ± 0.0014, tMCAO+SAG= 1.1 ± 0.17,
p < 0.05).
Neonatal hypoxia–ischemia injury is typically followed by
widespread inflammation involving parenchymal microglia and
astrocytes, which could contribute to secondary injury.23 To
investigate the effects of SAG treatment on gliosis, we
performed immunohistochemical analysis of activated microglia
(Iba1) and reactive astrocytes (GFAP) in gray matter regions
post-neonatal tMCAO. As shown (Fig. 2d, e), we observed a
decrease in ipsilateral Iba1 staining, which suggests decreased
microglial inflammation, and astrocytosis in tMCAO+SAG
compared to tMCAO+Veh animals. When quantified by
immunoblotting, both Iba1 and GFAP protein expression were
significantly increased in the ipsilateral hemisphere in tMCAO
+Veh compared to the sham groups but showed no significant
difference when SAG was administered (Sham+Veh= 1.05 ±
0.26; tMCAO+Veh= 7.58 ± 0.59; tMCAO+SAG= 1.55 ± 0.13, p <
0.01, Fig. 2f, g). These findings indicate that SAG treatment
induces Shh targets and may decrease inflammation and gliosis
following tMCAO.
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Fig. 2 SAG activates downstream Shh targets and decreases gliosis. a Brains collected 24 h post-surgery analyzed for protein expression of
the Shh downstream target Cyclin D1 (CCD1) expression in Sham+Veh, tMCAO+Veh, or tMCAO+SAG. Contra contralateral/uninjured
hemisphere, Ipsi ipsilateral/injured hemisphere. b Quantification of CCD1. c tMCAO brains collected 24 h post-surgery analyzed for mRNA
expression of Shh downstream target Gli1 using qRT-PCR. d Diagram showing striatum from infarct region of tMCAO brain, and representative
immunofluorescence images of Iba1, GFAP, or merged. Inset, higher magnification of cells positive for Iba1 and GFAP. Scale bar, 500 µm; inset,
20 µm. e Representative immunoblots of Iba1 and GFAP expression in Sham+Veh, tMCAO+Veh, or tMCAO+SAG brains. Contra contralateral/
uninjured hemisphere, Ipsi ipsilateral/injured hemisphere. f Quantification of Iba1 ipsilateral-to-contralateral expression ratio. g Quantification
































































Fig. 1 SAG administration following tMCAO improves brain volume. a Diagram of transient middle cerebral artery occlusion (tMCAO) injury
region in a coronal section of a rat brain, and experimental timeline for tMCAO and volume/cell fate analysis. Contra contralateral/uninjured
hemisphere, Ipsi ipsilateral/injured hemisphere. b Representative images of coronal sections from rat brains 2 weeks post-tMCAO or sham
surgery, at P24. c Quantification of brain volume following surgery and treatment, showing ratio of injured (ipsilateral) and uninjured
(contralateral) hemispheric volumes. d Quantification of corpus callosum volume following surgery and treatment. For quantification, mean ±
SEM; **p < 0.01 and ***p < 0.001 vs Sham+Veh, #p < 0.05 vs tMCAO+SAG; one-way ANOVA with Dunnett’s test. Veh injection of vehicle
solution (0.85% saline solution).
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SAG increases OPC proliferation following neonatal tMCAO and
adult demyelinating injury
Our analysis that SAG could improve hemispheric brain volume
preservation specifically showed improvements in the CC, which
could reflect axon preservation and/or support of myelinating
oligodendrocytes or OPCs. We next focused on the effects of SAG
treatment on the oligodendrocyte lineage. Using Olig2 as a pan-
lineage marker and BrdU+ co-labeling, we observed a significant
increase in proliferating OPCs in SAG-treated animals 14 days
post-tMCAO in the ipsilateral CC (tMCAO+Veh= 769 ± 371 vs.
tMCAO+SAG= 3400 ± 1235; p < 0.01, Fig. 3a, b) but not total
Olig2+ cells (Fig. 3c). This was associated with an increase in the
proportion of NKX2.2+ OPCs in the tMCAO+SAG group compared
to controls (Shams= 0.052 ± 0.023; tMCAO+Veh= 0.16 ± 0.023;
tMCAO+SAG= 0.27 ± 0.18; p < 0.01, Fig. 3d, e). However, despite
increased immature oligodendrocytes in the CC of SAG-treated
animals, we found that myelin basic protein labeling appeared
similar to Veh-treated controls (Fig. 3f) and that co-labeled mature
Olig2/CC1+ oligodendrocytes were similar in the two groups
(Fig. 3g, h).
To further interrogate the SAG effects on remyelinating
oligodendrocytes, we used a focal EB-induced demyelination
model12 in adult rats followed by one-time SAG or vehicle
injection (Fig. 4a, b). This model is characterized by demyelination
without axonal loss and has a well-established temporal sequence
of remyelination involving OPC proliferation (7 dpi) and differ-
entiation (14 dpi). The lesion area was determined by DAPI hyper-
cellularity, and we used NKX2.2/Ki67 and Olig2/CC1 to mark
proliferating OPCs and differentiated cells, respectively. As shown
(Fig. 4c, d), at 7 dpi there were increased numbers of newly
generated OPCs (Veh= 11 Nkx2.2 cells/mm2; SAG= 20 cells/mm2,
p < 0.05). There was an increase in the number of Olig2/CC1 at 7
dpi, which suggests a pro-differentiation effect of SAG on OPCs at
early time points; there was no differences at 14 dpi between the
vehicle and treated group. Staining for the Plp, a marker of myelin-
forming oligodendrocyte, showed an increase of the Plp+ cells:
however, this was not statistically significant (similar results
were found at 14 dpi tissue; there were no statistically
significant differences between the groups). Together, these
findings indicate that SAG treatment transiently increases















































































































































































Fig. 3 SAG increases oligodendrocyte proliferation but not differentiation following tMCAO. a Representative images showing
proliferating cells (BrdU+) in the corpus callosum (CC) positive for Olig2 in rats given tMCAO administered with saline (left) or SAG (right) at
P24. Scale bar, 50 μm. Inset, magnified view of single-channel immunostains. Arrows denote double-labeled cells. b Quantification of cells
double-labeled with BrdU and Olig2 in the CC. Black bars, CC from ipsilateral hemisphere; white bars, CC from contralateral hemisphere.
c Quantification of total Olig2+ cells in the CC in the ipsilateral hemisphere. d Representative images showing Olig2+ cells double-labeled
with Nkx2.2 in the CC in rats given tMCAO administered with saline (left) or SAG (right) at P24. Scale bar, 50 μm. Inset, magnified view of
single-channel immunostains. Arrows denote double-labeled cells. e Proportion of Nkx2.2+/Olig2+ cells in the CC of the ipsilateral
hemisphere in tMCAO+SAG vs tMCAO+Veh. f Representative images of the ipsilateral hemispheres stained for MBP (green) in P24 rats (left),
and insets shown at higher magnification (right). Scale bar, 500 μm. g Representative images showing Olig2+ cells double-labeled with CC1 in
the CC in rats given tMCAO administered with saline (top) or SAG (bottom). Scale bar, 20 μm. h Quantification of CC1+/Olig2+ cells in the CC
of the ipsilateral hemisphere in tMCAO+SAG vs tMCAO+Veh. *p < 0.05, one-way ANOVA with Tukey’s multiple comparisons test.
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oligodendrocyte proliferation at early stages post-injury but has
no sustained effects on differentiation and remyelination. Taken
together, these findings suggest that SAG treatment results in
increased CC volume and levels of OPC proliferation but not
oligodendrocyte differentiation or remyelination.
SAG promotes angiogenesis following tMCAO
Angiogenesis is a universal feature of wound healing across
tissues, and Shh has known effects in promoting vascular integrity.
To determine whether SAG treatment promoted vascular remo-
deling post-injury, we co-labeled sections harvested at P24 with
BrdU+ (proliferation) and Col4A (a vascular basement membrane
marker), to quantify endothelial cell (EC) proliferation in the
injured core following tMCAO or sham surgery (Fig. 5a). As
OPCs have been shown to play an important role in
endothelial proliferation and vascular development during cere-
bral development24 and under hypoxic conditions,4 we also
explored the possibility that an increase in OPC number is
associated with angiogenesis following injury and treatment. We
did observe a close association of proliferating oligodendrocytes
with the vasculature in the injured striatum in tMCAO+SAG
compared to tMCAO+Veh animals (Fig. 5b). Finally, immunohis-
tochemical analysis of Claudin-5 co-labeled with Col4A indicated
no significant change in expression or vascular coverage,
suggesting that SAG does not regulate endothelial tight junction
protein expression (Fig. 5c).
We observed a significant increase in the density of co-labeled,
newly generated ECs in tMCAO+SAG animals (1067 ± 163 cells
per hpf) vs tMCAO+Veh animals (578 ± 154, p < 0.05; Fig. 5d),
although there was no difference in vascular coverage (Fig. 5e),
which could be attributed to the relatively early time point chosen
for analysis.25 To determine whether endothelial proliferation
contributed to increased angiogenesis, we analyzed vascular
network features across cortical, striatal, and white matter
regions and found a significant increase in vessel branching in
tMCAO+SAG animals, consistent with endothelial proliferation at
this early time point (tMCAO+SAG= 49,447 ± 3189, tMCAO+
Veh= 35,068 ± 6268; p < 0.05; Fig. 5f). Given these findings, it is
possible that SAG-induced OPC proliferation is associated with the
pro-angiogenic response.
SAG improves long-term histology and cognitive function after
tMCAO
To determine the long-term efficacy of single-dose SAG treatment
after neonatal forebrain ischemia–reperfusion injury, we repeated
the P10 tMCAO experiment and analyzed this cohort in young
adulthood (Fig. 6a). At 8 weeks following tMCAO (P66), we used CR
testing to assess sensorimotor function and NOR as a test of
cognitive function and recognition memory. Brains were then
harvested for volume analysis (P72). As shown (Fig. 6b), while
there was no significant improvement in sensorimotor function
after SAG treatment, we observed a significant improvement in
cognitive function and recognition memory as assessed by NOR
(Fig. 6c). There was a significant decrease in the percentage of
novel object interaction in tMCAO+Veh compared to tMCAO
+SAG animals, which did not differ from shams (tMCAO+Veh=
0.44 ± 0.04, tMCAO+SAG= 0.58 ± 0.03, p < 0.05). Finally, we
observed a persistent improvement in hemispheric brain volume
at this later time point with SAG treatment (tMCAO+SAG= 0.56 ±
0.14, tMCAO+Veh= 0.73 ± 0.12, p < 0.05; Fig. 6d), along with
improved CC volume (tMCAO+Veh= 0.52 ± 0.06, tMCAO+SAG=
0.79 ± 0.06, p < 0.05; Fig. 6e, f).
DISCUSSION
In normal development, the Shh signaling pathway is crucial for
CNS patterning and cell fate specification,26 proliferation of
cerebellar granule neuron precursors,27 neural circuit and synapse
formation,28 vascular development,29 and oligodendrogenesis.30




























































lP injection Histology Histology
Fig. 4 SAG promotes oligodendrogenesis and maturation in an adult rat model of focal demyelination. a Schematic of EB model. b
Experimental timeline for focal demyelination using ethidium bromide (EB) injection into the rat cerebellar peduncle (CCP). c Representative
images of proliferating cells (Ki67, red) and OPCs (Nkx2.2, white) stained within the lesioned area (dotted lines) at 7 days post injury (dpi). Scale
bar, 25 μm. Inset, magnified view. Scale bar, 10 μm. Arrowheads denote cells double-positive for Ki67 and Nkx2.2. d Quantification of Nkx2.2
+/Ki67+ cells (top), and total Nkx2.2+ cells (bottom) from lesioned areas after vehicle or SAG administration. *p < 0.05, Student’s t test.
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rodent models of neonatal cerebellar injury, Down syndrome,8
and adult stroke.13 Here we extended these findings to a rat
model of NS and report the novel finding that a single dose of
SAG has beneficial effects to preserve brain volume, decrease
gliosis, increase endothelial and oligodendroglial lineage prolif-
eration, and enhance long-term behavioral outcomes.
SAG promotes oligodendroglial and endothelial proliferation after
brain injury
We examined the effect of post-injury SAG administration on
oligodendroglial lineage in two well-established preclinical brain
injury rodent models, tMCAO NS to examine the effects in
developing brain injury and EB-induced focal demyelination in
adult rats to focus on the oligodendroglial response.12 There was a
proliferative oligodendroglial response with SAG treatment in
both models. Recent work has shown that increased proliferation
is a prerequisite for the oligodendroglial differentiation31 and that
newly generated oligodendrocytes exhibit enhanced and accurate
axonal myelination.32 Although we did not see a significant
increase in mature CC1+ cells at these early time points, further
studies are needed to determine whether SAG-induced oligoden-
droglial proliferation might benefit myelin generation in the
long term.
Angiogenesis is critical for long-term repair following early focal
ischemia–reperfusion injury, but remarkably little is known regarding
































































































tMCAO + Veh tMCAO + SAGc
Col4a / Claudin5Col4a / Claudin5
Fig. 5 SAG enhances angiogenesis following tMCAO. a Cells in the injured core (striatum) stained with BrdU and Collagen 4A (Col4A), an EC
marker, to visualize proliferation of cells associated with the vasculature. Arrows denote BrdU+ cells in direct contact with Col4A+ vessels.
Scale bar, 100 μm. Right, diagram depicting area of analysis. b Cells co-stained with Olig2 and Col4A in the striatum. Arrows denote Olig2+
cells in contact with Col4A+ vessels. c Cells co-stained with Col4A and Claudin5, a marker of blood–brain barrier (BBB) structure.
d Quantification of BrdU+/Col4A+ cells in the ipsilateral striatum per mm3. e Quantification of vessel area from Col4A-labeled vasculature in
the motor and somatosensory cortical regions bordering the striatal core. f Quantification of vessel junction number per mm3 in the same
region as e. *p < 0.05, one-way ANOVA with Tukey’s multiple comparisons test.
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in the brain.33 In an adult stroke model, Shh administration increased
microvessel density and EC number 7 days after MCAO,13 while Smo
agonist cyclopamine blocked neuroprotective effects in early
subarachnoid hemorrhage.34 In our model of neonatal tMCAO, SAG
administration promoted OPC numbers and angiogenesis. We found
newly generated ECs in the injured core coupled with increased
vascular branching after SAG treatment, suggesting enhanced
vascular remodeling. Although we note that SAG did not regulate
endothelial tight junction based on Claudin 5 expression, we do not
rule out SAG affecting BBB permeability. Future extravasation studies
at different time points will provide insight into this.
In the developing embryonic and postnatal brain, the
vasculature engages in close interactions with migratory OPCs in
both mice and humans24 likely involving Wnt signaling during
development and the response to injury.4,24 In NS, we observed
increased numbers of oligodendroglial cells in close apposition to
blood vessels near the injured core in SAG-treated animals.
Whether SAG directly promotes vascular remodeling or is a
secondary consequence of oligodendrogenesis remains to be
elucidated.
One-time SAG treatment preserved brain volume and improved
behavioral outcomes long term after neonatal brain injury
We found that a single dose of SAG improved long-term
behavioral outcomes and brain volume in a model of NS. NOR
testing showed that treated animals had improved recognition
memory of objects over a length of time. In contrast, we did not
see long-term changes in sensorimotor function at young
adulthood by CR; however, there was significant variability within
groups, and this test may not adequately analyze fine motor










































































































































Fig. 6 SAG shows improvements in behavioral tests. a Experimental timeline for surgery, treatment, and behavioral tests for long-term
neurobehavioral outcome. b Quantification of gross sensorimotor function between groups as assessed by forelimb preference in the Cylinder
Rearing test. c Quantification of Novel Object Recognition test. d Quantification of ipsilateral-to-contralateral ratio of hemispheric brain
volume. e Quantification of ipsilateral-to-contralateral ratio of corpus callosum volume. f Representative images of coronal sections from rat
brains 2 months post-tMCAO or sham surgery. *p < 0.05, ***p < 0.001, ****p < 0.0001 vs Sham+Veh; #p < 0.05 vs tMCAO+SAG, one-way ANOVA
with Tukey’s multiple comparisons test.
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deficits at this time point following early injury. In addition, SAG
treatment significantly preserved brain volume indicating that it
has both short- and long-term benefit in a model of NS.
Potential therapeutic benefits of SAG in NS
NS constitutes a major health problem in the United States and
worldwide, with the majority of survivors exhibiting long-term
neurodevelopmental deficits.35,36 There are currently no accepted
small molecule neuroprotective interventions for NS, and such
therapies could be useful in acute settings outside major centers
that provide hypothermia, including low- and middle-income
countries.
Investigation of new treatment strategies for NS should take
into account both etiology and timing of injury to be as relevant
as possible to human newborn injury and thus translation to the
clinic.37 While erythropoietin has demonstrated consistent benefit
with post-injury treatment in different models of early brain injury,
including stroke,38 we note that multiple doses must be
administered and that single-dose therapy does not confer long-
term benefits.39 In contrast, our findings demonstrate clear
benefits of one-time treatment with SAG following tMCAO.
However, as we have measured SAG bioactivity duration in a
transgenic mouse model and not directly in our rat model, we
acknowledge that species differences may result in differential
responses. In addition, we note that prolonged bioactivity does
not imply that a single dose is either sufficient or most beneficial.
Future work will examine alternative treatment plan, such as
multiple doses or delayed therapy.
Mounting evidence suggests that SAG is neuroprotective
against injuries affecting preterm and term human neonates. We
found that SAG preserves brain volume and increases OPC
number, vascular proliferation, and long-term histological and
cognitive benefit with a single dose given immediately post-NS.
Therefore, this study supports investigation of SAG efficacy in
larger animal models and further translational development with a
view to ultimate testing in human clinical trials.
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